Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1013 for SHPT in Hemodialysis Patients
NCT06976177Phase 2Recruiting
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of MT1013 in secondary hyperparathyroidism (SHPT), sponsored by Shaanxi Micot Technology Co., Ltd. Primary endpoint: Occurrence of adverse events at 26 weeks. Started Jun 2024; status: recruiting.
02
Drugs
MT1013
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT06976177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06976177.